Novel conjugates of rgd-containing peptides and endogenous carriers

Abstract From the Canadian patent

Conjugates are prepared from RGD containing peptides by combining said , peptides or analog with a material providing a functionally reactive group capable of reacting with a blood component (preferably a mobile blood cell or endogenous protein). The conjugates may be administered to patients to provide antiplatelet or antiadhesion properties through the inhibition of the binding of fibrinogen to the GPIIb/IIIa receptor and may also be used as probes for , receptor activity. The administration to the patient may be made either in vivo or ex vivo and may be performed by either introducing the RDG containing peptide including the reactive functional group into the patient's vascular …